Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Edwards Lifesciences Corp sees FY 2014 revenue outlook at high end of prior range; raises FY 2014 EPS outlook; gives Q3 2014 mixed outlook


Tuesday, 29 Jul 2014 04:01pm EDT 

Edwards Lifesciences Corp:Expects FY 2014 total sales at the high end of its previous $2.05 - $2.25 bln range.Raised FY 2014 diluted earnings per share, excluding special items, to a range of $3.24 to $3.34.Expects Q3 2014 total sales to be between $530 -$570 mln.Expects Q3 2014 diluted earnings per share, excluding special items, to be between $0.66 and $0.72.FY 2014 revenue of $2.17 bln, EPS of $3.19 - Thomson Reuters I/B/E/S.Q3 2014 revenue of $527 mln, EPS of $0.74 - Thomson Reuters I/B/E/S. 

Company Quote

105.71
0.45 +0.43%
1:00pm EDT